Considering the significant survival benefits achieved by first-line PD-(L)1 blockade and chemotherapy in ES-SCLC (13, 17), data regarding neoadjuvant treatment are important and anticipated in LS-SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.